Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Fibrosis, and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Galectin-1/LGALS1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LGALS1 Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 expressed for native conformation. |
View LGALS1 Products |
| Gene Delivery | LGALS1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View LGALS1 Products |
| Benchmark Ab | Anti-LGALS1 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View LGALS1 Products |
| Validator | LGALS1 siRNA Set Target-specific knockdown verification in functional assays. |
View LGALS1 Products |
| Related Target A | LGALS3 (Galectin-3) Critical for selectivity screening; shares high structural homology with LGALS1. |
View LGALS3 Products |
| Related Target B | LGALS9 (Galectin-9) Synergistic immune checkpoint target co-expressed in the tumor microenvironment. |
View LGALS9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dimerization-dependent binding evaluation | HEK293 expressed LGALS1 preserving native homodimer-monomer equilibrium. |
| Subfamily cross-reactivity screening | Homology counter-screening panel including recombinant LGALS3 and LGALS9 (>95% purity). |
| Lack of controls | Clinical benchmark biosimilar antibodies available. |
| Target specificity validation | Validated siRNA sets included to confirm knockdown-induced phenotype changes. |
Live Galectin-1/LGALS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Galectin-1/LGALS1 therapeutics is intensifying, with major players shifting focus from traditional small-molecule carbohydrate mimetics to highly targeted monoclonal antibodies and bispecific configurations. As first-generation therapies reach the clinic, the next wave of R&D is targeting the reversal of immunotherapy resistance (particularly anti-PD-1/PD-L1 refractory solid tumors) and the modulation of extracellular matrix remodeling in fibrotic diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Galecto Biotech, Academic Institutes | Solid Tumors, Immune Evasion | Blockade Assay (Requires native glycosylated LGALS1 protein to mimic ligand binding) |
| Bispecific Antibody | Oncology Biotechs | Immune Checkpoint Synergy | Dual-targeting validation (Requires high-purity LGALS1 and partner targets like PD-1) |
| Small Molecule | Ascelia Pharma, Galecto Biotech | Myelofibrosis, Liver Fibrosis | Competitive binding assays (Requires high-purity, endotoxin-controlled recombinant LGALS1) |